How many insider trades does FilingIQ track for KLRS?

FilingIQ tracks 14 Form 4 insider transactions for KLRS (Kalaris Therapeutics, Inc.), covering filings from Mar 18, 2025 onwards. 5 of those were filed in the last 90 days.

Are KLRS insiders net buyers or net sellers?

Across the full Form 4 history for KLRS, 1 transactions (7%) were open-market purchases and 2 (14%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does KLRS insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is KLRS in?

Kalaris Therapeutics, Inc. (KLRS) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $122.87M.

KLRS insider trading

NasdaqGM Healthcare

Kalaris Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

7% / 14%

Market cap

$122.87M

About Kalaris Therapeutics, Inc.

Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was founded in 2019 and is headquartered in Berkeley Heights, New Jersey.

Company website: kalaristx.com

KLRS insider activity at a glance

FilingIQ has scored 14 insider transactions for KLRS since Mar 18, 2025. The most recent filing in our index is dated Mar 20, 2026.

Across the full history, 1 open-market purchases and 2 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on KLRS insider trades is 63.7/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live KLRS trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for KLRS?: FilingIQ tracks 14 Form 4 insider transactions for KLRS (Kalaris Therapeutics, Inc.), covering filings from Mar 18, 2025 onwards. 5 of those were filed in the last 90 days.
Are KLRS insiders net buyers or net sellers?: Across the full Form 4 history for KLRS, 1 transactions (7%) were open-market purchases and 2 (14%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does KLRS insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is KLRS in?: Kalaris Therapeutics, Inc. (KLRS) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $122.87M.

Methodology & sources

Every KLRS insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.